Are there benchmark values for mixing times for pharmaceutical powder blends for 500-1,000 litre batches?
For pharmaceutical powder mixtures with batch volumes of 500 to 1,000 litres, there are no generally binding mixing times. As an initial orientation, classic free-fall mixers such as V-, double-cone or bin mixers often lie in the range of approximately 10 to 20 minutes, while actively convective mixers such as ribbon, helical or plough-share mixers frequently allow shorter times. However, these values are only starting points for development; the final mixing time must be determined analytically and validated for each formulation, each mixer, and each batch size.
For free-fall or bin mixers, the total number of vessel rotations, rather than minutes alone, is often regarded as the transferable process variable. For simple mixtures with free-flowing, largely agglomerate-free components, practice often sets approximately 100 to 250 rotations as an initial trial range. At typical rotational speeds of, for example, 8 to 15 rotations per minute, this gives a rough time window of around 7 to 30 minutes. The number of rotations can provide useful orientation during scale-up, but it does not replace validation, because the flow pattern, fall height, air movement, segregation behaviour, and discharge can change with vessel size.
For convective mixers with actively driven tools, mixing times are often shorter still. Ribbon or band mixers frequently reach a mixing end point within a single-digit number of minutes for suitable, free-flowing products. Plough-share mixers or other intensive mixers can likewise achieve short times for demanding, cohesive or agglomerated powders, but they introduce more mechanical energy depending on tool speed and product resistance. Selection should therefore not be based on minimal mixing time alone. For pharmaceutical granulates or sensitive agglomerates, particle abrasion, changes to particle-size distribution, segregation, electrostatic charging, or a change in the subsequent tableting and flow properties can be more decisive than the duration of mixing.
Blanket time specifications are particularly inadequate for low-dose formulations with very small API proportions. In such cases, geometric dilution, a premix, or a matched dosing concept are often required. The order of raw-material addition is also relevant. A longer mixing time cannot reliably correct an unsuitable premix, and in extreme cases can intensify segregation or particle damage. Differences in particle size, particle shape, bulk density, cohesiveness, moisture, and electrostatic charging influence both the mixing kinetics and the stability of the mixture after mixing.
The fill level is a further central parameter. Free-fall mixers often work best within a limited fill-level window, because sufficient free surface must be available for reshuffling. Approximately 40 to 70 percent of the vessel volume is often chosen as a rough starting range. Overfilling can impede particle exchange; too low a fill level can reduce circulation or increase the risk of segregation. For rotating mixers, the suitable rotational speed is often described via the Froude number, which relates centrifugal and gravitational forces to one another: Fr = ω²R/g. For many industrial tumbler processes, a range below 0.2 is described in order to avoid undesired centrifuging of the bulk material.
In pharmaceutical development, the mixing time is not set from a single sample at the end of the process, but via a mixing-kinetics study. For this, batches are stopped after several different mixing times and examined according to a predefined sampling plan. In one published study, for example, samples were taken after 0.25, 0.5, 0.75, 1, 2, 5, 10 and 20 minutes from 13 positions; the mixing end point determined by HPLC there was five minutes, with an acceptable time window of between five and ten minutes. This example also shows that the required mixing time is highly product- and method-specific.
A commonly used internal orientation for blend uniformity is a relative standard deviation of at most 5 percent, combined with suitable criteria for the mean and individual values. This is not a universal substitute for a product-specific specification, but must be adapted to dose strength, analytical uncertainty, critical quality attributes, and regulatory strategy. For assessing spatial homogeneity, samples should be taken from several representative mixer positions. One FDA-related guidance cites at least ten sampling positions for the mixer; for convective mixers, up to 20 positions are recommended, in particular to include corners and the discharge area.
Mixing validation must not end at the mixing chamber. Particularly with 500 to 1,000 litre batches, a mixture can segregate again during discharge, at fall sections, through vibration, during pneumatic conveying, or in the holding vessel. Development should therefore also include temporally and spatially staggered samples during discharge, as well as, where applicable, samples at the inlet to the tablet press, capsule filling machine, or filling line. Content uniformity in the finished medicinal product is a critical quality attribute; inadequate blend uniformity or segregation can directly lead to variable dosing of the active ingredient.
PAT methods can support the determination of the mixing end point. Inline or online NIR, light-induced fluorescence, or other suitable measurement methods allow homogenisation to be observed more continuously and a robust mixing-time window to be established instead of a rigid single value. The benefit lies not only in a possible reduction of mixing time, but above all in the detection of under-mixing, over-mixing, or batch deviations. In one study, real-time NIR monitoring was confirmed by HPLC and stratified sampling, and showed a target value after three minutes for the formulation examined.
Short mixing times for large pharmaceutical batches
For pharmaceutical powder mixtures of 500 to 1,000 litres, there is no blanket mixing time, because the formulation, active-ingredient proportion, particle sizes, bulk densities, cohesiveness, fill level, and homogeneity requirements determine the mixing kinetics. amixon® therefore does not determine the required mixing time via general guide values, but through mixing trials with the original product. The result is a documented process window comprising charging sequence, fill level, mixing time, rotational speed, liquid addition where applicable, and discharge conditions. This approach is particularly important for low-dose formulations, where small quantities of active ingredient must be distributed uniformly within a large carrier mass.
Short mixing times arise when the mixing tool controllably reaches the entire batch volume and repeatedly reshuffles the product regions. The SinConvex® mixing tools of the amixon® vertical and cone mixers VM, HM and AM generate a three-dimensional product flow. The mixed material is conveyed upward near the wall, flows downward in the central region, and is then carried back into the mixing zone. The continuous product circulation supports uniform distribution of the components without requiring high tool speeds.
The HM vertical twin-shaft mixer uses two superimposed product streams. For suitable formulations, this design can enable short mixing times and high homogeneity. An HM can be used for batches in the range of 500 to 1,000 litres just as it can for considerably larger volumes. The specific size is determined on the basis of batch weight, bulk density, required fill level, feed concept, and available floor space. Standardised series reach up to approximately 20,000 litres; for larger requirements, special designs up to around 50 m³ are possible.
The KoneSlid® mixer KS works with an active, three-dimensional forced reshuffling. The product is conveyed upward in the outer region and flows back down centrally. A conical displacement body redirects the central product stream back toward the outer mixing zone. After around four tool rotations, the entire mixing volume can have been completely reshuffled once. Depending on the formulation, fill level, and target homogeneity, the technically ideal random mixture can be achieved after approximately 20 to 40 rotations. The KS combines this short mixing time with low mechanical stress and is therefore particularly suitable for sensitive, agglomerated or instantised products. However, the actual number of rotations required must be determined with the original product.
A wide fill-level range can increase flexibility for changing batch sizes. Depending on the design and product, amixon® mixers can be operated within a range of approximately 10 to 100 percent of the usable volume. However, the claim that mixing quality remains constant across the entire range must be confirmed for each individual formulation and apparatus size. Particularly with pharmaceutical mixtures, low fill levels, minor components, different bulk densities, or a low active-ingredient concentration can change the mixing kinetics. Process parameters and permissible batch sizes are therefore established as part of development, qualification, and, where applicable, process validation.
For large batches above approximately 2,000 litres, the Gyraton® GM can be used. This series is designed for large, gentle batch mixing and, according to the manufacturer, covers sizes of approximately 10 to 100 m³. Depending on the formulation and drive sizing, the mixer can be designed for short mixing times or for a particularly low-energy, gentle mode of operation. An assessment of the actual energy consumption and mixing time must be based on the real product and the planned batch.
Mixing time alone is not sufficient if the mixture segregates again during discharge or filling. A process-reliable solution must therefore also take discharge, downstream conveying equipment, and packaging into account. ComDisc® elements can support residual discharge and guide the product in a controlled way toward the outlet. With the KoneSlid®, the central closure system can open a large discharge cross-section, so that free-flowing products can be discharged very quickly. DosiFlap® valves enable low-dead-space, dosed filling of downstream containers. Whether these functions actually work free of segregation for a specific formulation must be checked with the original product across the complete discharge and filling process.
For pharmaceutical applications, amixon® apparatus can be executed to project-specific quality and hygiene requirements. Depending on the configuration, GMP-oriented designs, FDA-compliant materials and surfaces, EHEDG- and 3-A-compliant hygiene concepts, and sterile mixer or reactor designs are possible. amixon® supports the preparation and processing of Design Qualification, Installation Qualification and Operational Qualification. Automation and documentation can be aligned with EU-GMP and FDA 21 CFR Part 11. Which regulatory requirements are actually met is defined in the User Requirement Specification and the project-specific configuration.
More than 30 test units in various sizes are available at the amixon® pilot plant in Paderborn. Additional pilot plants exist in Japan, India, Thailand, China, South Korea and the USA. Trials can be carried out with the original product, realistic fill levels, the intended batch sizes, and the planned temperature and pressure conditions. Mixing quality, mixing time, product protection, energy input, cleanability, residual discharge, and reproducibility are assessed. For pharmaceutical formulations, the sampling strategy, analytical method, active-ingredient content at different mixer positions, and the stability of the mixture during discharge should additionally be examined.